make ppt of ARMD(age related macular degeneration) from standard textbook from basic to advances in detail, include clinical trials and recent advances, add flowcharts and tables and images wherever necessary. write in chat

Reading File

Finding Sources

Searching PubMed

"age-related macular degeneration"[MeSH Terms] AND treatment

Reading File

Searching PubMed

"macular degeneration"[MeSH Terms] AND "anti-VEGF"

Reading File

Searching PubMed

"macular degeneration" AND "gene therapy" AND "complement"

Searching the Web

ARMD age related macular degeneration clinical trials 2024 2025 faricimab pegcetacoplan gene therapy

Loading Image

Reading File

Loading Image

Reading File

Running Command

Writing File

Running Command

Editing File

Running Command

Editing File

Running Command

Your presentation is ready:

ARMD Comprehensive
Presentation · PPTX
(6.1 MB, 30 slides)

What's Inside — Slide by Slide

The deck uses a dark navy/teal color scheme with a bold clinical design. Here's what's covered:

#	Section	Type
1	Title Slide	Visual
2	Outline	Color-coded 12-module index
3	Epidemiology	Key stats — 8.5% global blindness, 1.75M US patients
4	Normal Macular Anatomy	RPE, Bruch membrane, choriocapillaris
5	AREDS Classification	Table: 5-stage grading with action steps
6	Pathogenesis Diagram	Real Robbins figure — dry vs wet comparison
7	Dry AMD Pathogenesis	CFH/CFI genetics, complement, lipofuscin, drusen
8	Wet AMD Pathogenesis	CNV, VEGF, Ang-2, disciform scar
9	Risk Factors	Split layout: modifiable vs non-modifiable
10	Genetics	CFH Y402H, ARMS2/HTRA1, GWAS, complement genes
11	Clinical Features	Split: Dry vs Wet symptoms/signs
12	Fundus Photo — Dry AMD	Real clinical photo with fine drusen
13	Fundus Photo — Wet AMD	Hemorrhage, exudates, CNV
14	Visual Field Simulation	Stadium photo showing central scotoma
15	Differential Diagnosis	Table: 8 conditions vs AMD
16	Investigations	OCT, FFA, ICGA, FAF, OCT-A
17	FFA + Fundus dual image	Side-by-side comparison
18	Dry AMD Flowchart	9-step management algorithm
19	AREDS/AREDS2 Evidence	Trial details, supplement formula, smoker caveat
20	Anti-VEGF Agents Table	Pegaptanib → Faricimab with doses, approvals, notes
21	Anti-VEGF Mechanism	VEGF, Ang-2, T&E rationale
22	Wet AMD T&E Flowchart	Step-by-step treat-and-extend protocol
23	PDT (Verteporfin)	Mechanism, indications, side effects
24	Wet AMD Trials Table	MARINA, ANCHOR, CATT, VIEW, HAWK, TENAYA, PULSAR, AVONELLE-X
25	Dry AMD Trials Table	AREDS, AREDS2, OAKS/DERBY, GATHER, PHOENIX, 4FRONT, ArMaDa
26	Complement Therapies	Pegcetacoplan, avacincaptad pegol (both FDA 2023)
27	Gene Therapy	RGX-314, 4D-150, ADVM-022, OCU410 — Phase 3 trials 2025
28	Other Emerging Treatments	EYP-1901, OTX-TKI, stem cells, AI, photobiomodulation, tinlarebant
29	Monitoring & Prognosis	OCT protocols, Amsler grid, PHP home monitoring
30	Key Take-Home Messages	7 bullet summary in dark themed cards
31	References	13 citations — textbooks + recent PubMed literature

write it in chat, the file can't be downloaded

Here is the complete ARMD presentation written directly in chat, from basics to advanced, with all tables, flowcharts, and images inline.

👁️ AGE-RELATED MACULAR DEGENERATION (ARMD)

A Comprehensive Review — Basic to Advanced

Sources: Harrison's 22E · Goldman-Cecil Medicine · Robbins Pathology · Wills Eye Manual · Goodman & Gilman · Katzung Pharmacology · AREDS/AREDS2 · PubMed 2023–2026

📋 OUTLINE

#	Module
01	Epidemiology & Global Burden
02	Normal Macular Anatomy
03	Classification & Staging
04	Pathogenesis
05	Risk Factors & Genetics
06	Clinical Features & Symptoms
07	Investigations & Imaging
08	Dry AMD — Management
09	Wet AMD — Anti-VEGF Therapy
10	Landmark Clinical Trials
11	Emerging Therapies & Gene Therapy
12	Monitoring, Prognosis & Rehabilitation

01. EPIDEMIOLOGY & GLOBAL BURDEN

Key Statistics

Parameter	Data
Global blindness attributable to AMD	~8.5% of all blindness
US prevalence	>1.75 million persons
Global affected (2020 estimate)	~196 million
Projected global (2040)	~288 million
Cumulative incidence at age ≥75	8%
Age of onset (typical)	6th–9th decade
Second eye CNV risk (after unilateral wet AMD)	10–12% per year
Laterality	Bilateral in most cases

Key Points

Leading cause of irreversible central vision loss in adults >55 years in developed countries
Prevalence doubles with each decade after age 55
Predominantly affects industrialized nations
Major driver of low-vision services and quality-adjusted life year (QALY) loss
Peripheral vision is preserved throughout — central vision selectively affected
"Individuals with advanced disease can walk down a street without difficulty but cannot recognize facial features" — Harrison's 22E

02. NORMAL MACULAR ANATOMY

Structural Layers Relevant to ARMD

VITREOUS
    ↓
INNER RETINA (ganglion cells, bipolar cells)
    ↓
OUTER NUCLEAR LAYER (photoreceptor nuclei)
    ↓
PHOTORECEPTORS — Rods & Cones
    ↓
RETINAL PIGMENT EPITHELIUM (RPE) ← Key target in ARMD
    ↓
BRUCH MEMBRANE (5-layered) ← Site of drusen formation
    ↓
CHORIOCAPILLARIS ← Sole blood supply to outer retina
    ↓
CHOROID (large vessels)
    ↓
SCLERA

The Critical Functional Unit (Robbins Pathology)

RPE + Bruch Membrane + Choriocapillaris = the core functional triad Disturbance in any one component → photoreceptor damage → vision loss

Structure	Normal Function	Role in ARMD
RPE	Phagocytose shed photoreceptor outer segments; retinoid recycling; blood-retinal barrier	Accumulates lipofuscin; RPE atrophy in dry AMD
Bruch Membrane	5-layer barrier between RPE and choroid; supports RPE attachment	Drusen deposit here; calcification; CNV penetrates through here
Choriocapillaris	Sole vascular supply to outer retina and RPE	Obliterated in geographic atrophy
Fovea/Foveola	Highest cone density; sharpest central acuity	Primary site of ARMD damage
Macula lutea	~5.5 mm central retinal area temporal to disc	Yellow pigment (lutein/zeaxanthin) — protective role

03. CLASSIFICATION & STAGING

AREDS Classification System

Stage	Drusen Size	Pigment Changes	Vision	Management
No AMD	None or small (<63 μm)	None	Normal	Routine review
Early AMD	Medium drusen (63–124 μm)	Absent	Usually normal	Lifestyle; monitor
Intermediate AMD	Large drusen (≥125 μm) OR pigment change	Present	May have subtle changes	AREDS2 supplements
Late AMD — Dry (GA)	Any + geographic atrophy	RPE atrophy, well-defined	Significant central loss	Supplements; complement inhibitors; rehab
Late AMD — Wet (nAMD)	Any + choroidal neovascularization (CNV)	SRF, hemorrhage, exudate	Acute central loss	URGENT anti-VEGF

Two Forms Summarized

Feature	Dry AMD	Wet AMD
Frequency	90% of all AMD	10% of AMD
Mechanism	Complement-mediated atrophy	Choroidal neovascularization (CNV)
Speed of progression	Slow (months–decades)	Rapid (days–weeks)
Vision loss	Gradual, moderate	Sudden, severe
Drusen	Always present	Usually present
Hemorrhage	Absent	Present
Treatment	Supplements; C3/C5 inhibitors	Anti-VEGF injections
Relationship	Usually precedes wet AMD	Complication of dry AMD (not inevitable)

04. PATHOGENESIS

Pathogenesis Diagram (from Robbins Pathology, Fig 29.24)

Dry vs Wet AMD schematic showing risk factors: Aging, Genetic predisposition, Oxidative stress, Complement activation → Dry AMD: drusen formation, damage to RPE, damage to photoreceptor cells → Wet AMD: neovascularization, subretinal hemorrhage, intraretinal fluid

Fig 29.24 — Robbins, Cotran & Kumar Pathologic Basis of Disease: Schematic illustrating the differences between dry and wet AMD. Dry AMD may progress to wet AMD, and in some patients both forms may coexist.

Dry AMD Pathogenesis

AGING + GENETIC SUSCEPTIBILITY (CFH, ARMS2) + OXIDATIVE STRESS (SMOKING)
                            ↓
            Impaired RPE function
                            ↓
    Accumulation of LIPOFUSCIN in RPE cells
    (oxidized polyunsaturated fatty acids + vitamin A dimers = A2E toxin)
                            ↓
    DRUSEN formation in Bruch membrane
    (focal lipoprotein deposits; hard → soft → confluent)
                            ↓
    Activation of COMPLEMENT SYSTEM (alternative pathway)
    (CFH/CFI variants → excess complement activity)
                            ↓
    Chronic subclinical inflammation → RPE cell death
                            ↓
    GEOGRAPHIC ATROPHY (GA)
    (loss of RPE + choriocapillaris + photoreceptors → central blind spot)

Key Molecules in Dry AMD:

CFH (Complement Factor H): major regulator of alternative complement pathway — Y402H variant in 35% of AMD cases
CFI (Complement Factor I): serine protease that inactivates C3b
C3, C9: effector complement proteins found in drusen
Lipofuscin / A2E: phototoxic waste products accumulating in stressed RPE

Wet AMD Pathogenesis

DRY AMD (geographic atrophy or large drusen)
                    ↓
RPE cells under HYPOXIA / OXIDATIVE STRESS
                    ↓
Overexpression of VEGF-A (Vascular Endothelial Growth Factor A)
+ Angiopoietin-2 (Ang-2) — destabilizes existing vessels
                    ↓
Neovascular sprouting from CHORIOCAPILLARIS
                    ↓
New vessels penetrate BRUCH MEMBRANE
                    ↓
CHOROIDAL NEOVASCULARIZATION (CNV) under RPE or subretinal space
                    ↓
Frail neovascular channels LEAK plasma, lipids → subretinal exudates
                    ↓
SUBRETINAL HEMORRHAGE → acute central visual loss
                    ↓
Organization by RPE cells → DISCIFORM SCAR (macular fibrosis)
                    ↓
IRREVERSIBLE CENTRAL VISUAL LOSS

CNV Types (by location):

Type	Location	Angiographic appearance
Classic CNV (Type 2)	Above RPE, subretinal	Well-defined, bright early leakage on FFA
Occult CNV (Type 1)	Below RPE	Fibrovascular PED; late irregular leakage
RAP (Type 3)	Intraretinal origin	Focal telangiectatic vessels; IRF + RPE detachment
PCV	Polypoidal dilations of inner choroid	Serosanguineous PED; ICGA characteristic

05. RISK FACTORS & GENETICS

Risk Factor Summary

Category	Risk Factor	Relative Risk
Non-modifiable	Advanced age	Strongest factor
	Family history	3–4× if first-degree relative
	White/European ancestry	Higher than Asian/African
	Female sex	Slight increase
	Hyperopia	Increased risk
	Light iris color (blue/grey)	Modest increase
Modifiable	Cigarette smoking	2–4× increase (strongest modifiable)
	Systemic hypertension	Increased risk
	High dietary fat, low lutein/zeaxanthin	Increased risk
	Obesity / metabolic syndrome	Increased risk
	Sedentary lifestyle	Modest increase
	Chronic UV exposure	Modest increase
Ocular	Soft large drusen (≥125 μm)	Major risk for progression
	RPE pigment clumping	Risk for CNV development
	Wet AMD in fellow eye	10–12% per year CNV risk in other eye
Nutritional	Low serum lutein, zeaxanthin	Modifiable
	Omega-3 deficiency	Modifiable

Genetics of ARMD

ARMD is polygenic and multifactorial — GWAS identified >40 susceptibility loci

Gene / Locus	Chromosome	Function	Risk Allele
CFH Y402H	1q32	Complement Factor H — regulates alternative pathway	rs1061170 — 2–4× risk
ARMS2/HTRA1	10q26	ARMS2 function unclear; HTRA1 is a serine protease	rs10490924 — major risk
C3	19p13	Central complement effector	R102G variant
CFI	4q25	Inactivates C3b — dampens complement	Variants increase activity
CFB / C2	6p21	Alternative / classical pathway	Protective haplotype known
C9	5p13	Terminal complement complex	Variants identified
VEGF pathway	Various	Neovascular susceptibility	Multiple loci

Genetic Model:

Genetic susceptibility (CFH + ARMS2) × Environmental exposure (smoking, diet) = Clinical phenotype

(Thompson & Thompson Genetics and Genomics in Medicine, 9th ed.)

06. CLINICAL FEATURES & SYMPTOMS

Dry AMD — Symptoms & Signs

Symptoms:

Gradual, insidious loss of central vision (months to years)
Amsler grid distortion (metamorphopsia)
Difficulty reading, watching TV, recognizing faces
Often asymptomatic in early/intermediate stages
Peripheral vision preserved throughout

Signs on Fundus Examination:

Drusen — small hard (bright, discrete) → soft (large, indistinct, >125 μm) → confluent
RPE pigment clumping — hyperpigmented spots in outer retina
Geographic atrophy (GA) — well-defined areas of RPE depigmentation with visible choroidal vessels
Bilateral involvement (typically asymmetric)

Fundus Photo: Dry AMD with Fine Drusen (Wills Eye Manual)

Fundus photograph showing dry AMD — multiple scattered yellow-white drusen visible across the macula, with the dark foveal center and optic disc visible

Figure 11.16.1 — Dry AMD with fine drusen. Multiple hard and soft drusen scattered in the macula. Absence of hemorrhage or exudate. (Wills Eye Manual, 7th Ed.)

Wet AMD — Symptoms & Signs

Symptoms:

Sudden onset central or paracentral scotoma
Acute metamorphopsia (lines appear wavy, distorted)
Photopsias (flashes) in central visual field
Rapid, profound central visual loss (hours to days)

Signs on Fundus Examination (Wills Eye Manual, Section 11.17):

Critical: Drusen + subretinal fluid (SRF), macular edema (ME), or RPE detachment associated with CNV
Subretinal or intraretinal hemorrhage
Retinal exudates (hard exudates/lipid deposition)
Subretinal fibrosis (disciform scar) — late stage
Retinal angiomatous proliferation (RAP) — intraretinal telangiectatic vessels with focal hemorrhage
Pigment epithelial detachment (PED)

Fundus Photo: Wet (Exudative) AMD (Wills Eye Manual)

Fundus photograph showing wet AMD — subretinal hemorrhage, yellow exudates, irregular pigmentation and a grayish-green CNV membrane near the macula

Figure 11.17.1 — Exudative AMD. Note the subretinal hemorrhage, exudates and irregular pigmentation consistent with active choroidal neovascularization. (Wills Eye Manual, 7th Ed.)

Visual Field in ARMD

Stadium photograph demonstrating ARMD visual field — a large dark central scotoma covers the entire playing field while the peripheral stands remain visible

Fig F24.3.1 — Simulated visual field in ARMD. The central vision (playing field) is absent due to macular changes. Peripheral vision (stadium stands) remains intact. Patients are taught eccentric fixation to maximize remaining vision. (Histology: A Text and Atlas, Pawlina)

Differential Diagnosis

Condition	Key Differentiating Features	Age	Drusen
Dry AMD	Bilateral, macular drusen, RPE atrophy, slow progression	≥55	Yes — macular
Wet AMD	CNV, subretinal fluid/blood, rapid loss, urgency	≥55	Usually present
Peripheral drusen	Drusen only peripheral to macula; no central involvement	Variable	Yes — peripheral
Myopic degeneration	High myopia, lacquer cracks, peripapillary changes, no drusen	Any	No
CSCR	RPE/serous detachment, young males, self-limiting, no drusen	<50	No
Stargardt disease	Familial, yellow-white flecks, early onset, ABCA4 mutation	<50	No (flecks)
Pattern dystrophy	Bilateral macular pigment changes, familial, <50 years	<50	No
Chloroquine toxicity	Bull's-eye maculopathy, ring hyperpigmentation, drug history	Any	No
Ocular histoplasmosis	White chorioretinal scars, peripapillary atrophy, endemic	Any	No
Angioid streaks	Subretinal red-brown bands radiating from disc	Any	No
IPCV	Polypoidal choroidal dilations, serosanguineous PED, ICGA	≥50	Sometimes

07. INVESTIGATIONS & IMAGING

Workup Algorithm

PATIENT WITH SUSPECTED ARMD
           ↓
1. Best Corrected Visual Acuity (ETDRS/Snellen)
           ↓
2. Amsler Grid (10° central field, both eyes)
           ↓
3. Slit-Lamp Biomicroscopy + Dilated Fundus Exam
   (90D / 78D lens — grade drusen, RPE changes)
           ↓
4. OCT (Optical Coherence Tomography) — MANDATORY
   [Cross-sectional retinal imaging: SRF, IRF, drusen, PED]
           ↓
    ┌──────────────────────────────────────┐
    ↓                                      ↓
DRY AMD                               WET AMD suspected
    ↓                                      ↓
FAF (Fundus Autofluorescence)         FFA (Fluorescein Angiography)
→ GA extent, RPE viability            → CNV leakage characterization
    ↓                                      ↓
Document, monitor                     + OCT-A (non-invasive CNV mapping)
                                           ↓
                                   ± ICGA (if PCV suspected)

Imaging Modalities Compared

Modality	What It Shows	Key Use in ARMD
Fundus Photography	Color retinal image	Baseline documentation; drusen grading
OCT (gold standard)	Cross-section retinal layers; SRF, IRF, PED, drusen volume	Diagnosis + treatment monitoring of wet AMD
FFA (Fluorescein Angiography)	Leakage, CNV type, extent	Classic vs occult CNV; leakage pattern
ICGA (Indocyanine Green)	Choroidal circulation, polyps	PCV diagnosis; type 1 occult CNV
FAF (Fundus Autofluorescence)	RPE metabolic activity (lipofuscin signal)	GA extent, margins; progression tracking
OCT-A	Blood flow in retinal/choroidal layers non-invasively	CNV detection without dye injection
Amsler Grid	10° central field distortion	Home monitoring; detect metamorphopsia
PHP (ForeseeHome)	Preferential Hyperacuity Perimetry	Home monitoring device; FDA cleared

FFA in Wet AMD

Fluorescein angiogram of exudative AMD showing a large dark area with irregular hyperfluorescent patches representing CNV leakage and blocked fluorescence from hemorrhage

Figure 11.17.2 — Intravenous fluorescein angiography of exudative AMD. The hyperfluorescent areas indicate CNV leakage; dark areas represent blocked fluorescence from subretinal hemorrhage. (Wills Eye Manual, 7th Ed.)

08. DRY AMD — PREVENTION & MANAGEMENT

Management Flowchart: Dry AMD

┌─────────────────────────────────────────────────────┐
│         EARLY DRY AMD                               │
│   Small/medium drusen, no central visual symptoms   │
└─────────────────────┬───────────────────────────────┘
                      ↓
┌─────────────────────────────────────────────────────┐
│         LIFESTYLE MODIFICATION                      │
│  • STOP SMOKING (most important single intervention)│
│  • UV-blocking sunglasses                           │
│  • Mediterranean diet (leafy greens, omega-3)       │
│  • Control blood pressure, blood sugar, lipids      │
│  • Regular aerobic exercise                         │
└─────────────────────┬───────────────────────────────┘
                      ↓
┌─────────────────────────────────────────────────────┐
│     INTERMEDIATE DRY AMD                           │
│   Large drusen (≥125 μm) or pigment changes         │
└─────────────────────┬───────────────────────────────┘
                      ↓
┌─────────────────────────────────────────────────────┐
│         AREDS2 SUPPLEMENTS (daily)                  │
│  Vitamin C 500 mg                                   │
│  Vitamin E 400 IU                                   │
│  Lutein 10 mg + Zeaxanthin 2 mg                     │
│  Zinc 80 mg + Copper 2 mg                           │
│  (Beta-carotene AVOIDED — lung cancer risk in smokers)│
└─────────────────────┬───────────────────────────────┘
                      ↓
┌─────────────────────────────────────────────────────┐
│      HOME MONITORING                                │
│  Daily Amsler grid / ForeseeHome PHP device         │
│  Any new metamorphopsia → URGENT CLINIC REVIEW      │
└─────────────────────┬───────────────────────────────┘
                      ↓
┌─────────────────────────────────────────────────────┐
│    ADVANCED DRY AMD / GEOGRAPHIC ATROPHY (GA)       │
└─────────────────────┬───────────────────────────────┘
                      ↓
┌────────────────────────────────────────────────────────────────┐
│   COMPLEMENT INHIBITORS (FDA approved 2023):                   │
│   Pegcetacoplan (Syfovre) — C3 inhibitor                       │
│     Monthly or every-other-month IVT injection                 │
│     OAKS trial: ~22% reduction in GA lesion growth             │
│   Avacincaptad pegol (Izervay) — C5 inhibitor                  │
│     Monthly IVT injection                                      │
│     GATHER2: ~14.5% reduction in GA growth vs sham             │
└────────────────────────────────────────────────────────────────┘
                      ↓
┌─────────────────────────────────────────────────────┐
│       LOW VISION REHABILITATION                     │
│  • Magnification spectacles, video magnifiers       │
│  • Eccentric fixation training                      │
│  • Large-print / e-reader technology                │
│  • Orientation & mobility training                  │
│  • Psychosocial support / Macular Society           │
└─────────────────────────────────────────────────────┘

AREDS & AREDS2 Trials — Key Evidence

Trial	Year	n	Key Finding
AREDS	2001	4,757	Supplements (Vit C/E + beta-carotene + zinc/copper) reduced progression from intermediate → advanced AMD by 25% (NNT ~8 over 5 years)
AREDS2	2013	4,203	Replacing beta-carotene with lutein/zeaxanthin (10 mg/2 mg): similar efficacy; safer in smokers — no increase in lung cancer risk

Important Caveats:

Beta-carotene NOT recommended for smokers/recent ex-smokers — 28% increased lung cancer risk (ATBC and CARET trials)
AREDS2 formula is now the standard recommendation
Supplements do NOT benefit early AMD or prevent AMD in healthy eyes
Diet: high lutein/zeaxanthin (kale, spinach), omega-3 (oily fish), low glycaemic index

09. WET AMD — ANTI-VEGF THERAPY

Anti-VEGF Agents: Pharmacology & Comparison

Agent	Class	Mechanism	Dose	FDA Approval	Notes
Pegaptanib (Macugen)	Aptamer	Binds VEGF165 isoform only	0.3 mg IVT q6w	2004	First approved; largely superseded
Ranibizumab (Lucentis)	Fab fragment	Binds all VEGF-A isoforms	0.5 mg IVT	2006	Monthly → PRN/T&E; landmark MARINA/ANCHOR
Bevacizumab (Avastin)	Full IgG1 antibody	Binds VEGF-A	1.25 mg IVT	Off-label	Non-inferior to ranibizumab (CATT); compounded; very widely used
Aflibercept 2 mg (Eylea)	Fusion protein (decoy receptor)	Binds VEGF-A, VEGF-B, PlGF	2 mg IVT	2011	Q8w after 3 monthly loads; VIEW 1&2
Brolucizumab (Beovu)	Single-chain Fv (scFv)	Pan-VEGF-A	6 mg IVT	2019	Q12w; smaller molecule; rare retinal vasculitis/occlusion risk
Aflibercept 8 mg (Eylea HD)	Fusion protein (higher dose)	Same as above	8 mg IVT	2023	Q12–16w dosing; PULSAR/PHOTON trials
Faricimab (Vabysmo)	Bispecific IgG antibody	Anti-VEGF-A + Anti-Ang-2	6 mg IVT	2022	Up to Q16w; TENAYA/LUCERNE; dual pathway

(Source: Goodman & Gilman's Pharmacological Basis of Therapeutics, Table 74-15)

Mechanism of Action — Anti-VEGF Agents

HYPOXIA / OXIDATIVE STRESS in RPE
              ↓
    VEGF-A overexpression
              ↓
    Binds VEGFR1/VEGFR2 on endothelial cells
         ↓                    ↓
  ANGIOGENESIS           PERMEABILITY↑
(new vessel sprouting)  (fluid leakage)
         ↓                    ↓
    CNV growth          SRF / IRF / PED
              ↓
         ┌────────────────────────────────┐
         │     ANTI-VEGF AGENTS          │
         │  Block VEGF → halt CNV growth │
         │  Reduce vascular permeability │
         │  → Dry macula on OCT          │
         └────────────────────────────────┘

FARICIMAB DUAL MECHANISM:
Anti-VEGF-A + Anti-Ang-2
     ↓               ↓
Block new CNV    Stabilize existing vessels
             ↓
      Superior vascular stability
             ↓
      Longer dosing intervals (up to Q16w)

Treat-and-Extend (T&E) Protocol — Wet AMD

STEP 1: CONFIRM WET AMD
OCT (SRF / IRF / PED) + BCVA + FFA/OCT-A
              ↓
STEP 2: LOADING PHASE
3 monthly IVT injections (fixed interval)
              ↓
STEP 3: ASSESS RESPONSE ON OCT
              ↓
    ┌─────────────────┴──────────────────┐
    ↓                                    ↓
MACULA DRY                          FLUID PRESENT
(no SRF/IRF)                        (SRF or IRF)
    ↓                                    ↓
EXTEND interval by 2 weeks          MAINTAIN or SHORTEN
(Q6w → Q8w → Q10w → Q12w → Q16w)   interval by 2 weeks
    ↓                                    ↓
CONTINUE T&E                        Re-assess next visit
              ↓
PERSISTENT FLUID at maximum interval (Q4w)
              ↓
SWITCH anti-VEGF agent
(e.g., ranibizumab → faricimab → aflibercept 8mg)
              ↓
REASSESS after 3 injections of new agent

Treatment Goals:

Achieve anatomically dry macula on OCT (no SRF, no IRF)
Maintain or improve BCVA
Reduce injection burden while maintaining disease control

Photodynamic Therapy (PDT) — Verteporfin

(Goodman & Gilman, Chapter 74)

Feature	Detail
Drug	Verteporfin (Visudyne) 2 mg/mL
Route	IV infusion (dosed by body surface area)
Mechanism	Drug circulates to choroidal vasculature → non-thermal 689 nm laser activation → free radical generation → platelet activation → thrombosis → CNV occlusion
Half-life	5–6 hours; excreted in feces
Indication (classic)	Predominantly classic subfoveal CNV in wet AMD
Side effects	Photosensitization (avoid sunlight 5 days), transient visual disturbance, back pain (IV infusion)
Current role	Limited in anti-VEGF era; combination therapy in polypoidal choroidal vasculopathy (PCV)

10. LANDMARK CLINICAL TRIALS

Wet AMD Trials

Trial	Year	Drug	n	Design	Key Result
MARINA	2006	Ranibizumab 0.3/0.5 mg	716	Phase 3 RCT vs sham	95% maintained vision; 35% gained ≥15 letters (vs 5% sham)
ANCHOR	2006	Ranibizumab vs PDT	423	Phase 3 RCT	Ranibizumab superior to PDT in all visual outcomes — established anti-VEGF as standard of care
CATT	2011	Ranibizumab vs Bevacizumab	1,208	Non-inferiority RCT	Bevacizumab non-inferior to ranibizumab at 2 years; PRN=monthly outcomes; major cost-saving implications
VIEW 1 & 2	2012	Aflibercept 2 mg vs Ranibizumab	2,457	Phase 3 RCT	Q8w aflibercept non-inferior to monthly ranibizumab; reduced injection burden — first extended dosing
HAWK/HARRIER	2019	Brolucizumab 6 mg vs Aflibercept	1,817	Phase 3 RCT	Non-inferior; 56% on Q12w; rare retinal vasculitis/occlusion (1–3.3%) — post-marketing safety signal
TENAYA/LUCERNE	2022	Faricimab 6 mg vs Aflibercept	1,329	Phase 3 RCT	Non-inferior; ~80% on ≥Q12w; bispecific Ang-2 + VEGF-A mechanism validated → FDA approval Jan 2022
PULSAR	2023	Aflibercept 8 mg vs Afl 2 mg	669	Phase 3 RCT	Q12–16w dosing achieved; non-inferior → FDA approval Aug 2023 (Eylea HD)
AVONELLE-X	2025	Faricimab long-term extension	800+	Extension study	~80% on Q12–16w at 4 years; durable with no new safety signals (AAO 2025 data)

Dry AMD / Geographic Atrophy Trials

Trial	Year	Drug	n	Key Result
AREDS	2001	Antioxidant vitamins + zinc	4,757	25% reduction in progression to advanced AMD; defined standard supplement formula
AREDS2	2013	Lutein/zeaxanthin replacing beta-carotene	4,203	Similar efficacy; safer in smokers — no lung cancer risk increase
FILLY	2018	Lampalizumab (CFD inhibitor)	906	Promising Phase 2 results in CFI-positive patients; Phase 3 failed (negative 2018)
OAKS/DERBY	2023	Pegcetacoplan (C3 inhibitor)	637	~20–22% reduction in GA lesion growth vs sham → FDA approved Feb 2023
GATHER1/GATHER2	2021–23	Avacincaptad pegol (C5 inhibitor)	~500	~14.5% reduction in GA growth; foveal sparing preserved → FDA approved Aug 2023
PHOENIX	2025	Tinlarebant (RBP4 inhibitor, oral)	~500	Phase 3 ongoing — reduces retinol delivery to RPE → slows GA progression
ArMaDa	2025	OCU410 (nuclear receptor modifier gene therapy)	~60	Phase 1/2 ongoing — Ocugen modifier gene therapy for GA
4FRONT	2025	4D-150 (gene therapy dual anti-VEGF/VEGF-C RNAi)	400	Phase 3 ongoing — single IVT injection for sustained anti-VEGF

11. EMERGING & GENE THERAPIES

Complement-Based Therapies (FDA Approved 2023)

Drug	Target	Trial	Result
Pegcetacoplan (Syfovre, Apellis)	C3 (complement 3) inhibitor	OAKS/DERBY Phase 3	22% (monthly) / 18% (EOM) reduction in GA growth; IVT injection
Avacincaptad pegol (Izervay, Iveric Bio/Astellas)	C5 (complement 5) inhibitor	GATHER1 & 2	14.5% reduction in GA; preserved foveal sparing; monthly IVT
BI 771716 (Boehringer Ingelheim)	Novel target	VERDANT Phase 2	Active-controlled vs pegcetacoplan — ongoing 2025
VOY-101 (Voyager)	C3 — gene therapy	JOURNEY Phase 1/2	First gene therapy targeting complement for GA

Rationale: CFH/CFI genetic variants → insufficient complement regulation → excess C3/C5 activation → RPE destruction → GA progression. Blocking C3 (upstream) or C5 (downstream) slows this cascade.

Gene Therapy Pipeline

The concept: a single intravitreal injection of a viral vector (AAV) transfects retinal cells to produce therapeutic proteins continuously — eliminating the injection burden of monthly IVT anti-VEGF.

Program	Company	Vector/Target	Stage (2025)	Route
RGX-314	AbbVie / Regenxbio	AAV8-anti-VEGF (ranibizumab-like Fab)	AAVIATE Phase 2 + ASCENT Phase 3 (n=500)	Subretinal / suprachoroidal
ADVM-022 / Ixo-vec	Adverum Biotechnologies	AAV.7m8-anti-VEGF	LUNA Phase 2 + ARTEMIS Phase 3 (n=400)	IVT single injection
4D-150	4D Molecular Therapeutics	AAVv66-anti-VEGF + VEGF-C RNAi	PRISM Phase 1/2 + 4FRONT Phase 3 (n=400)	IVT single injection
OCU410	Ocugen	Nuclear receptor modifier (RORA gene)	ArMaDa Phase 1/2	IVT
VOY-101	Voyager	C3 inhibitor gene therapy	JOURNEY Phase 1/2	IVT
SAR402663	Sanofi	AAV-anti-VEGF	Phase 1/2	IVT
LX102-C01	Lees Pharmaceutical	Anti-VEGF gene therapy	Phase 1 — 12-month safety data published 2025	IVT

If successful: one injection every 2–5 years vs current 6–12 injections per year

Other Emerging Treatments

Approach	Drug / Device	Mechanism	Stage
Sustained-release TKI	EYP-1901 (Vorolanib)	Biodegradable intravitreal implant releasing tyrosine kinase inhibitor (anti-VEGF pathway)	Phase 3 LUCIA/LUGANO (2025)
Sustained-release TKI implant	OTX-TKI (Axitinib, Ocular Therapeutix)	Biodegradable hydrogel depot in vitreous; anti-VEGFR	Phase 3 (2025)
Bispecific novel	AXT107 (AsclepiX)	Peptide blocking VEGFR2 + αvβ3 integrin	Phase 1/2 DISCOVER
Stem cell therapy	iPSC-derived RPE cells	Replace diseased RPE in dry AMD	Early clinical trials
Oral RPE protection	Tinlarebant (Belite Bio)	RBP4 inhibitor — reduces subretinal accumulation of all-trans-retinol (A2E precursor)	Phase 3 PHOENIX (2025)
Photobiomodulation	LumiThera device	670 nm light → stimulates mitochondrial activity, reduces drusen/inflammation	NCT04065490 Phase 3
Neuroprotection	Elamipretide (Stealth BioTherapeutics)	Mitochondrial-targeted peptide	Phase 3 ReNEW (2025)
AI / Digital health	AI-OCT platforms	Automated fluid detection, progression prediction, screening	Entering clinical integration

12. MONITORING, PROGNOSIS & REHABILITATION

Monitoring Protocol by Disease Stage

Stage	Frequency	Tools	Action Triggers
Early dry AMD	Annual	Dilated exam + OCT	New symptoms → urgent review
Intermediate dry AMD	Every 6 months	OCT + FAF + daily Amsler	Metamorphopsia → same-week assessment
Advanced dry (GA)	Every 3–6 months	OCT + FAF (GA area)	Consider complement inhibitor; low vision referral
Wet AMD — on treatment	Per T&E protocol (Q4w–Q16w)	OCT + BCVA every visit	Recurrent fluid → shorten interval; non-response → switch drug
Fellow eye monitoring	Every 3–6 months	OCT + Amsler	CNV in fellow eye — urgent treatment

Home Monitoring Tools

Tool	Description	Advantage
Amsler Grid	10° central field distortion grid	Free, instant, daily use
ForeseeHome (PHP)	Preferential Hyperacuity Perimetry device	FDA-cleared; early CNV detection; telemedicine link

Prognosis

Scenario	Prognosis
Dry AMD — early/intermediate	Slow progression; supplements reduce 25% conversion risk
Dry AMD — geographic atrophy	Progressive; no cure; complement inhibitors slow growth ~15–22%
Wet AMD — untreated	60–70% lose ≥3 lines of vision within 2 years
Wet AMD — with anti-VEGF (current)	~95% maintain vision; 30–40% gain ≥15 letters (3 lines)
Wet AMD — gene therapy (future)	Long-term single-injection control — Phase 3 results awaited

Predictors of Poor Visual Outcome:

Late presentation (>6 weeks from symptom onset)
Large subretinal hemorrhage
Subfoveal CNV at baseline
Subretinal fibrosis / disciform scar
Poor anti-VEGF response after 3 loading doses

Low Vision Rehabilitation

Optical aids: high-plus reading glasses, hand/stand magnifiers, binoculars for distance
Electronic aids: video magnifiers (CCTV), e-readers with adjustable font, screen-reading software
Eccentric fixation training: using peripheral retina for tasks previously done by fovea
Orientation & mobility: safe navigation, home adaptations
Psychological support: depression is common with AMD-related vision loss; CBT, peer support
Legal & social support: registration as visually impaired; DVLA/DMV driving regulations
Support organizations: Macular Society, AMD Alliance International, Fighting Blindness

📌 KEY TAKE-HOME MESSAGES

#	Message
1	ARMD is the leading cause of blindness in adults >55 — bilateral, progressive, affects central vision only; peripheral vision is preserved
2	Two forms: Dry (90%, slow, complement-driven drusen/atrophy) and Wet (10%, rapid, VEGF-driven CNV) — dry precedes wet but both may coexist
3	Pathogenesis: RPE + Bruch membrane + choriocapillaris is the critical unit; CFH/ARMS2 variants + smoking + aging = AMD phenotype
4	AREDS2 supplements reduce progression by 25% in intermediate AMD — avoid beta-carotene in smokers; lutein/zeaxanthin is the safer alternative
5	STOP SMOKING — the single most impactful, cost-free intervention; doubles risk if continued
6	Wet AMD = ophthalmic emergency — urgent anti-VEGF (faricimab or aflibercept 8 mg first-line); treat-and-extend protocol; goal = dry macula on OCT
7	Geographic atrophy now treatable (2023): Pegcetacoplan (C3 inhibitor) and avacincaptad pegol (C5 inhibitor) — first-ever FDA-approved drugs for dry AMD
8	Gene therapy is coming — single IVT injection for sustained anti-VEGF production; RGX-314, 4D-150, ADVM-022 all in Phase 3 trials (2025)

📚 REFERENCES

Harrison's Principles of Internal Medicine, 22nd Edition (2025, McGraw Hill) — Chapter 391, Sections on Macular Degeneration
Goldman-Cecil Medicine International Edition — Section 391: Age-Related Macular Degeneration
Robbins, Cotran & Kumar: Pathologic Basis of Disease — Chapter 29: Retina — Age-Related Macular Degeneration (Figs 29.24, 29.25)
The Wills Eye Manual, 7th Edition — Sections 11.16 (Dry AMD) & 11.17 (Wet AMD)
Goodman & Gilman's Pharmacological Basis of Therapeutics — Chapter 74: Ocular Pharmacology, Table 74-15
Katzung's Basic & Clinical Pharmacology, 16th Edition — Macular Degeneration (Block 12)
Histology: A Text and Atlas with Correlated Cell and Molecular Biology (Pawlina) — Chapter 24, Clinical Correlation ARMD
Thompson & Thompson Genetics and Genomics in Medicine, 9th Ed — GWAS in AMD
AREDS Research Group (2001). Arch Ophthalmol. Original supplement trial
AREDS2 Research Group (2013). JAMA. Lutein/zeaxanthin substitution
Kalavar M, Sridhar J. Clinical trials examining faricimab and high-dose aflibercept for wet AMD. Curr Opin Ophthalmol 2025. PMID: 39937692
Marchesi N et al. Different Therapeutic Approaches for Dry and Wet AMD. Int J Mol Sci 2024. PMID: 39684764
Rowe LW, Ciulla TA. Gene Therapy for Non-Hereditary Retinal Disease. Genes (Basel) 2024. PMID: 38927656
Wheeler S et al. Treatment for dry AMD: where we stand in 2024. Curr Opin Ophthalmol 2024. PMID: 38869976
Clinical Trial Update May 2025. Retinal Physician — faricimab CONSTANCE, 4D-150 4FRONT, VERDANT, PHOENIX trials

End of ARMD Comprehensive Review — Orris Medical Education, June 2026

Search for latest 2026 retinal imaging studies on OCT-A in wet AMD

Searching PubMed

"optical coherence tomography angiography" AND "neovascular age-related macular degeneration"

Searching the Web

OCT-A optical coherence tomography angiography wet AMD neovascular 2026 study retinal imaging

Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.

This is a shared conversation. Sign in to Orris to start your own chat.